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Abstract
Background: It is uncertain whether the replication of systematic reviews, particularly those with the same objectives
and resources, would employ similar methods and/or arrive at identical findings. We compared the results
and conclusions of two concurrent systematic reviews undertaken by two independent research teams provided with
the same objectives, resources, and individual participant-level data.
Methods: Two centers in the USA and UK were each provided with participant-level data on 17 multi-site clinical trials
of recombinant human bone morphogenetic protein-2 (rhBMP-2). The teams were blinded to each other’s methods and
findings until after publication. We conducted a retrospective structured comparison of the results of the two systematic
reviews. The main outcome measures included (1) trial inclusion criteria; (2) statistical methods; (3) summary efficacy and
risk estimates; and (4) conclusions.
Results: The two research teams’ meta-analyses inclusion criteria were broadly similar but differed slightly in trial inclusion
and research methodology. They obtained similar results in summary estimates of most clinical outcomes and adverse
events. Center A incorporated all trials into summary estimates of efficacy and harms, while Center B concentrated on
analyses stratified by surgical approach. Center A found a statistically significant, but small, benefit whereas Center B
reported no advantage. In the analysis of harms, neither showed an increased cancer risk at 48 months, although Center
B reported a significant increase at 24 months. Conclusions reflected these differences in summary estimates of benefit
balanced with small but potentially important risk of harm.
Conclusions: Two independent groups given the same research objectives, data, resources, funding, and time produced
broad general agreement but differed in several areas. These differences, the importance of which is debatable, indicate
the value of the availability of data to allow for more than a single approach and a single interpretation of the data.
Systematic review registration: PROSPERO CRD42012002040 and CRD42012001907.
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Background
Systematic reviews and meta-analyses [1] based on individ-
ual participant-level data (IPD) from randomized controlled
trials (RCTs) are considered to provide the highest level of
rigor for evaluating the evidence for a clinical question [2].
Such reviews offer the possibility of using hierarchical
statistical techniques that better handle sources of hetero-
geneity, allow for sub-group analyses, and facilitate assess-
ment of rare events. Previously, IPD meta-analyses have
modified [3–8] or overturned [9] the results of previous
meta-analyses based on the published literature alone.
Efficient and unbiased mechanisms to replicate research
findings are essential for maintaining high levels of scien-
tific credibility [10]. The premise of replication efforts is
that different groups, employing rigorous methods, may
take different approaches and come to different conclu-
sions on a previously addressed question. Recent efforts to
promote data sharing by the National Institutes of Health,
[11, 12] the pharmaceutical industry, [13, 14] and partner-
ships between academia and industry [15, 16] have made
replication an increasingly available mechanism to test the
validity of clinical trial conclusions. This work is particu-
larly important for systematic reviews and meta-analyses,
which frequently form the basis of professional society
and government guideline recommendations [17].
Previous studies have sought to determine whether sys-
tematic reviews are replicable, with new teams performing
new searches, summaries, and analyses of the literature
for a particular question. These studies, which compare
systematic reviews of the published literature conducted
at different time points, suggested that groups investigat-
ing the same research question may differ in their findings
[18–21], though most often, these differences were attrib-
uted to search strategy [6, 19, 22–25]. However, it is un-
certain if replication of meta-analyses, particularly those
with the same research objectives, participant-level
data, time, and funding, would employ the same ana-
lytic methods or arrive at identical findings. A thorough
understanding of the reliability of meta-analysis re-
quires an empiric assessment of how two distinct teams
of investigators would employ meta-analytic techniques
to address the same clinical question. Accordingly, we
sought to determine if two independent centers, each
of which were contracted to pursue identical research
questions concurrently, with access to identical IPD,
would employ identical methods in the areas of data use
and statistical analysis and report identical, or at least
consistent, results and conclusions.
Methods
Study design
We retrospectively compared the research methods and
results of the final comprehensive publications of two
meta-analyses performed in the context of full systematic
reviews of recombinant human bone morphogenetic
protein-2 (rhBMP-2) prepared by two independent
centers, Center A [26, 27] from the University of York
and Center B [28, 29] from Oregon Health & Science
University, and focused on (1) meta-analysis trial inclusion
criteria; (2) statistical methods; (3) summary risk estimates;
and (4) conclusions.
Trial inclusion criteria were defined as study charac-
teristics necessary for inclusion in meta-analysis. We ex-
plicitly compared, for primary and secondary endpoint
meta-analyses, as well as safety analyses, the trials used
by both centers for each analysis. For methods, we com-
pared centers’ reported outcomes at various time points
as well as statistical methods. We compared the centers’
risk estimates for all primary outcomes for efficacy as
well as safety at all time points. In consideration of these
factors, we provide a subjective comparison of the over-
all conclusions drawn by each center.
Conducting the systematic reviews and IPD meta-analysis
Following controversy in the literature surrounding
adverse events related to rhBMP-2 including cancer, in
August 2011, Medtronic agreed to participate in the
Yale University Open Data Access (YODA) Project model,
which has been described previously (Fig. 1) [30].
Appendix 1 provides additional context on the particu-
lar clinical controversy covered by these reviews. Our
analysis will focus on systematic review reproducibility
rather than this particular clinical question which has
already been well described in the literature. An open
request for proposal was announced by the YODA
Project to solicit applications from external investiga-
tors with preliminary research aims to study the safety
and efficacy of rhBMP-2. The YODA Project selected
research groups from Oregon Health & Science Uni-
versity (OHSU) and the University of York in the UK
(York). These leading centers specialize in the conduct
of systematic reviews and bring internationally recog-
nized primary investigators who have made significant
contributions to methodology development for organi-
zations including the Cochrane Collaboration and the
Agency for Healthcare Research and Quality (AHRQ).
Based on feedback from OHSU and York, a set of rec-
onciled aims were developed to ensure a common
scope (Table 1) [31]. Each group independently devel-
oped its protocol for conducting the systematic review
and deposited the full protocol with the YODA Project.
Both groups registered short versions of their protocols
without detailed methods for analysis on the PROSPERO
registry of systematic reviews on February 23, 2012
(CRD42012002040 and CRD42012001907).
The YODA Project transferred the full set of Medtronic
data relating to rhBMP-2 to the centers in early December
2011. This included full de-identified individual participant-
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level data for 17 trials, consisting of 8 pilot studies, 8 pivotal
RCTs, and 1 study terminated for commercial reasons. The
total number of participants was 2091, consisting of 1077
rhBMP-2 recipients and 1014 control participants. Also in-
cluded were protocols, data dictionaries, internal reports
consisting of summaries of study data, and brief adverse
event case histories. In addition, 1229 MedWatch adverse
event reports submitted to the US Food and Drug Admin-
istration between July 2003 and July 2012 were provided.
Each center completed IPD meta-analyses on the ef-
fectiveness and harms of rhBMP-2 in the context of full
systematic reviews. Each site was responsible for deter-
mining the appropriateness of conducting a systematic
review as well as its methods and research questions
within the scope of the specified research aims. The pro-
ject was designed so the review groups would work in
parallel and have no mutual communication about their
approaches. Questions from the groups were communi-
cated through the YODA Project review coordinator so
that there was no direct communication between the
groups and Medtronic.
Draft reports of comprehensive findings were received
from both groups by the YODA Project in mid-August
2012. These reports were peer-reviewed by separate re-
view teams consisting of members of the YODA Project
and steering committee, which included clinical, statis-
tical, and methodological experts, as well as by a
representative from Medtronic. A peer reviewer had ac-
cess to only one of the two reports at any time before
final publication, and there was no communication be-
tween the separate review teams. Comments were returned
to the research groups in September 2012. The groups pre-
pared separate manuscripts for submission for publication
in the Annals of Internal Medicine. Final reports of com-
prehensive findings, which reflected peer review comments
from the journal and from the YODA Project, were re-
ceived in summer 2013. These comprehensive reports,
which we review in this paper, were published on the
YODA Project website congruently with the articles in the
Annals on June 18, 2013. The data set has subsequently
been made available to additional researchers through a re-
quest process [32]. The Human Investigation Committee
at Yale University determined that this study is not consid-
ered to be Human Subjects Research and did not require
further review.
Results
Meta-analysis inclusion criteria
Trial inclusion was largely similar with a primary differ-
ence of IPD obtained from a single published RCT. Both
centers chose only to include RCTs of rhBMP-2 in spinal
fusion in their meta-analysis, and both groups analyzed
11 of the RCTs. Center A obtained IPD from, and included
an additional non-industry sponsored RCT by, Glassman
Fig. 1 YODA Project timeline for the independent synthesis and meta-analysis of rhBMP-2 clinical trials, including their publication
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et al. [33] for its analysis of effectiveness but excluded it
when looking at harms since events were reported differ-
ently and without information on when they occurred.
Though Center B identified this study, it did not solicit
IPD from its authors and was able to include only a quali-
tative analysis.
Research methodology
Research methodology differed primarily in the choice of
stratification, with minor differences in the choice of
statistical methods. For analyses of benefits, Center A in-
cluded trials that compared rhBMP-2 with standard
bone grafting techniques across all surgical approaches.
As the primary analysis, Center A performed a standard
two-stage meta-analysis along with a sub-group analysis
that did not find evidence of differences between surgi-
cal approaches.
Center B stratified by surgical approach for effective-
ness and most harms and determined that only two of
the four surgical approaches (anterior lumbar interbody
fusion (ALIF) and posterolateral fusion (PLF)), which
were studied in multiple RCTs, provided adequate data
for meta-analysis. Center B employed a one-stage meta-
analysis, using mixed effects regression models. The study
comparing rhBMP-2 with lumbar disc prosthesis was in-
cluded in the analysis of cancer and death, which was not
stratified by surgical approach.
Both centers studied the same primary outcomes for
effectiveness and reported them at the same time points
of 6 weeks and 3, 6, 12, and 24 months after surgery
(Table 2).
Table 1 Explicit research aims provided to the 2 independent
centers by the YODA Project
Research aims
1. Identify all relevant studies, across all uses and sponsor (i.e., Medtronic
sponsored, others).
2. Determine the questions that were addressed by these studies.
3. Evaluate the quality of the studies. Assess the risk of bias associated
with the design, conduct, and reporting of each clinical study, including
those identified via the systematic review and those provided by
Medtronic, and, if present, how bias may have affected assessment of
effectiveness and harms.
(a) Assessment of study design and conduct should include evaluation
of internal validity, methods used to ascertain outcomes and other
policies and procedures for data collection, as well as the integrity of
case report form adjudication.
(b) Assessment of study reporting should include selective publication
and selective reporting
(c) Summary of these findings should include:
i. What conclusions can be drawn by assessing the full body of data
and what gaps in knowledge remain, taking into account results from
the evaluation of quality and risk of bias
ii. An assessment of applicability of these studies
4. Conduct meta-analyses from studies identified via the systematic review,
if appropriate, and using patient-level data, if possible. If not appropriate
there should be another approach to summarizing the data. The analysis
should consider the following:
a. For effectiveness, meta-analysis should consider patient-centered
outcomes (i.e., quality of life and functional status), as well as surrogate
outcomes (i.e., fusion as determined by radiography).
b. For safety, meta-analysis should include local effects such as inflammation,
heterotopic bone formation, pain, osteolysis and instability, and
downstream or systematic effects such as leg pain and weakness,
retrograde ejaculations, and possible increased risk of cancer.
Table 2 Results from meta-analyses conducted independently
by Centers A and B examining measures of efficacy and safety
associated with rhBMP-2
Outcome Center Surgical
approach
No. of
studies (n)
Effect size
(95% CI)
Treatment
advantage
ODI A All 12 (1368) (0-100) -3.48
(-6.47 to -0.49)
BMP
B ALIF 5 (423) (0-50) -7.35
(-14.00 to -0.70)
BMP
PLF 4 (650) (0-50) -1.98
(-4.86 to 0.90)
Neither
SF-36 PCS A All 12 (1303) (0-100) 1.93
(0.63 to 3.22)
BMP
B ALIF 5 (421) (0-100) 3.68
(0.86 to 6.49)
BMP
PLF 4 (644) (0-100) 1.10
(-0.6 to 2.86)
Neither
Back pain A All 12 (1326) (0-10) -1.58
(-2.65 to -0.51)
BMP
B ALIF 4 (409) (0-20) -0.74
(1.49 to 0.00)
BMP
PLF 4 (649) (0-20) -0.31
(-0.76 to 0.15)
Neither
Leg pain A All 12 (1326) (0-10) -0.59
(-1.27 to 0.09)
Neither
B ALIF 4 (409) (0-20) -0.60
(-1.28 to 0.08)
Neither
PLF 4 (648) (0-20) -0.34
(-0.82 to 0.13)
Neither
Fusion A All 10 (1078) RR 1.14
(1.03 to 1.25)
BMP
B ALIF 5 (416) RR 1.05
(0.88 to 1.24)
Neither
PLF 4 (637) RR 1.16
(0.96 to 1.41)
Neither
Cancer A All up to
48 months
11 (1281) RR 1.98
(0.86 to 4.54)
Neither
B All 24
months
5 (1450) RR 3.45
(1.98 to 6.00)
Control
All 48
months
4 (1183) RR 1.82
(0.84 to 3.95)
Neither
CI Confidence Interval, ODI Oswestry disability index. Lower favors
rhBMP-2. ALIF Anterior lumbar interbody fusion, PLF Posterolateral fusion,
RR Relative risk, SF-36 PCS Short Form 36 Physical Component Score.
Higher favors rhBMP-2. For back and leg pain, Center A used a 0-10 scale
and Center B used a 0-20 scale. Lower favors rhBMP-2. Bolded values
statistically significant
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Similar outcomes were also reported between the centers
for harms up to 4 weeks and then up to 24 months for
general adverse events, and up to 48 months for cancer
and death.
Neither group found evidence of an rhBMP-2 dose-
response relationship or heterogeneity in groups that
received high-dose forms of rhBMP-2, so all dose for-
mulations were combined.
For harms, Center A chose to combine all trials using
a generalized mixed effects model since specific adverse
events were few at the trial level. Center B also used a
generalized mixed effects model with stratification by
surgical approach, except for cancer and death.
Summary results estimates
The groups obtained similar results in summary estimates
of most clinical outcomes and adverse events, although
there were notable differences. Center A found a statisti-
cally significant increase in fusion rate at 24 months
(12% over controls) combining data across all surgical
approaches. In contrast, Center B, reporting results for
each surgical approach separately, did not find a signifi-
cant increase in fusion at 24 months. For reducing back
pain and overall disability, Center A found a statistically
significant advantage for all time points from 6 months
onwards when combining data from all approaches, with
no statistically significant difference in the effectiveness of
rhBMP-2 by surgical approach (Fig. 2). For Center B, dif-
ferences for pain reduction were statistically significant
from 3 months onward for ALIF, but only at the 6-month
time point for PLF.
Findings were not identical for cancer; Center B re-
ported a statistically significant increased risk at 24 months
with the use of rhBMP-2, and Center A did not report at
24 months. Neither group found a significantly increased
risk of cancer associated with rhBMP-2 at 48 months
(Fig. 2). Both groups reported similar but not identical
findings for the frequency of regular adverse events.
Summary conclusions
Center A interpreted benefits to fusion and postoperative
pain as “clinically insignificant” and increased cancer inci-
dence as “inconclusive,” noting that “whether this increased
risk is genuine is uncertain” (Table 3). Overall, by this ana-
lysis alone, rhBMP-2 seemed to offer improved rates of fu-
sion with similar clinical outcomes compared with standard
techniques at the expense of increased reports of back and
leg pain in the early postoperative period.
In contrast to Center A’s report, Center B found “moder-
ate-strength evidence of no consistent differences between
rhBMP-2 and ICBG in…fusion rates.” In addition, it re-
ported a statistically significant increase in cancer at
the 24-month time point, while noting that “This finding
should be interpreted with caution because cases were
heterogeneous.” Overall conclusions from Center B
seemed to indicate more strongly than those of Center A
that rhBMP-2 had no additional clinical benefit. Center B
reported that its “analysis underscores that more definitive
evidence about harms was needed before rhBMP-2
Fig. 2 Forest plots from Center A and Center B meta-analyses examining likelihood of bone fusion and cancer risk associated with rhBMP-2
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became widely used” and that “On the basis of the cur-
rently available evidence, it is difficult to identify clear
indications for rhBMP-2 in spinal fusion. This analysis
shows almost no clinical benefit for the product while
raising questions about the potential risk for cancer.”
Discussion
In our study of two independent centers provided with
identical objectives, data, resources, and time to conduct
concurrent meta-analyses, we found that the centers did
not report identical methods, results, and interpretations.
In addition, the potential benefit of additional analyses of
the same data was not limited solely to increasing confi-
dence through replication. Separate analyses revealed nu-
ances of differences, with potential interpretations for
clinical management, which could be produced from the
same data set using valid methods. These findings, even
though largely similar, support the case for greater sharing
and access to clinical data as a way to maximize public
dialogue about the meaning of the data and to ensure that
a single interpretation does not lead people to believe
there is no other possible approach.
The centers took different but methodically defensible
approaches in their attempts to best represent the re-
sults of this data set in a relevant and valid way. Review
methods differed based on data stratification and IPD
obtained from an additional trial. One group chose to
combine data across all surgical approaches, finding little
heterogeneity in trials by approach. The other group
chose to stratify and analyze by surgical approach, forgo-
ing increased statistical power in recognition of the real
differences and adverse event concerns between different
surgical approaches, and to present in a format perhaps
more intuitive to spine surgeons. Study inclusion di-
verged, with one group obtaining IPD from an additional
trial not funded by Medtronic and including it in the
analysis of effectiveness. Even with the proliferation of
standards in methodology, this demonstrates that we
can expect some differences in how two similarly quali-
fied groups might choose to conduct a complex system-
atic review. This diversity in methods has the potential
to add to the depth of our understanding of a product
and reinforces that additional value can be tapped from
a data set with open access.
These differences in approach led to differences in
summary estimates. In the case of the outcome of spinal
fusion, this led to a difference that had statistical relevance
even as the group discounted the clinical importance.
Nevertheless, this finding could support the argument in
the spine literature that the use of this product is war-
ranted in certain indications and select cases where the
risk of non-union is great and its consequences potentially
disastrous [34, 35]. In contrast, this difference was no
longer detectable when data were stratified by a surgi-
cal approach in the other review, and surgeons looking
at these data alone might see fewer instances where this
product would be beneficial. For estimates of cancer,
there were slight differences in the time points reported.
Center B showed a statistically significant increase in can-
cer at the 24-month time point but concurred that cancer
was not significantly increased for longer follow-up. In
both cases, the absolute risk of cancer was low, and the
cancer types represented were heterogeneous.
In contrast to previous studies of concurrent meta-
analyses in nutrition and endometrial cancer [7] and im-
munotherapy treatments for spontaneous abortions, this
study found that concurrently conducted meta-analyses
examining the same data arrived at conclusions that readers
may or may not interpret similarly. Currently, it ap-
pears that nearly all meta-analyses are conducted by
single groups, without replication. Additional analyses
necessitate the sharing of data, and this in itself can
bring important benefits. Information in the published
literature is often incomplete. Data sharing has the poten-
tial to allow for a more complete picture of the benefits
and harms of a treatment based on the totality of available
evidence. Data are often collected or subsidized at the
public expense and need to be made more widely available
for the public benefit. Across a diverse array of fields, open
access to data and the potential for reanalysis can, at the
minimum, strengthen confidence in the findings of a
Table 3 Conclusions made by Centers A and B after
conducting independent summary reviews and meta-analysis of
rhBMP-2 trials
Center Conclusions
A “At 24 months, rhBMP-2 increases fusion rates, reduces pain by
a clinically insignificant amount, and increases early postsurgical
pain compared with ICBG. Evidence of increased cancer
incidence is inconclusive.”
“The use of rhBMP-2 in spinal fusion surgery increases the
likelihood of successful fusion at up to 24 months, but this does
not seem to translate into a clinically significant reduction in
pain. The small improvements in fusion and in the level of pain
reduction, which manifest after 6 months, also seem to come at
the expense of more frequent pain in the immediate
postoperative period and, possibly, an increased number of
cancer cases. We believe that it is important that clinicians
explain these findings to patients so that they can make
informed choices about the type of surgery they would prefer.”
B “In spinal fusion, rhBMP-2 has no proven clinical advantage over
bone graft and may be associated with important harms,
making it difficult to identify clear indications for rhBMP-2.”
In conclusion, we found…no evidence that rhBMP-2 is more
effective than ICBG in spinal fusion, with some evidence of an
association with important harms. More research is needed to
provide more reliable estimates of risk for cancer and other
adverse events and to identify patient populations in which use
of rhBMP-2 may be beneficial, such as cases where use of bone
graft alone is associated with a high risk for pseudarthrosis. On
the basis of the currently available evidence, it is difficult to
identify clear indications for rhBMP-2 in spinal fusion.”
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systematic review while offering the potential to add to
or even alter the conclusions about an intervention.
While there are many benefits and arguments for
greater data sharing, these benefits must be considered in
light of potential downsides that might come with add-
itional analyses based on the same data. In this project, we
addressed industry concerns around spurious analysis and
litigation, as well as biased and methodologically flawed
studies which might unfairly taint a product. Academia
too faces challenges around credit, bias, and the potential
for conflicting messages to confound decision-making.
Ultimately, we believe a process of frameworks, like the
YODA Project, and norms can help manage these po-
tential problems and unlock the benefits that come
with greater sharing of data.
The generalizability of our findings to other settings is
not known. However, the design of our approach should
have made it more likely that the results would have been
the same rather than different. The two groups were pro-
vided with the same data from all manufacturer-sponsored
studies which, for rhBMP-2, represented the vast majority
of high-quality studies on this product. Studies of the other
questions could be limited by differences in search strat-
egies and disagreement over key studies. The groups also
received identical funding from an outside organization,
and neither the groups nor the funders had any financial
interest in this product.
Conclusions
Two independent and expert review groups that performed
independent meta-analyses of rhBMP-2 came to broadly
similar findings, though with some differences on the stat-
istical significance of primary analyses of fusion and cancer.
The clinical importance of the differences may be debat-
able, and even the authors of this article differed in their
interpretations of the results and conclusions presented in
these analyses. What is certain is that the methods and
interpretations were not identical and had different
points of emphasis. This underscores the importance of
making data more openly available for the purpose of
additional scientific inquiry to maximize the knowledge
that can be extracted.
Appendix 1
rhBMP-2 background and summary findings
Clinical background: spinal fusion is a commonly per-
formed surgery to correct spinal instability and commonly
accompanies spinal decompressions among other uses. To
improve the rate of fusion if local bone is insufficient, sur-
geons often use graft material. Autologous iliac crest bone
graft (ICBG) is considering the gold standard for grafting
but often involves harvesting bone from a separate site
through a separate incision.
Recombinant bone morphogenetic protein-2 (rhBMP-2)
is an orthobiologic that promotes bone formation and
spinal fusion that is used as an alternative to ICBG. It is
approved for anterior lumbar interbody fusion (ALIF)
surgery but was widely used in other surgical approaches
with off-label use estimated at 85% [36] and peak sales
approach $1 billion [37].
Adverse events attributed to rhBMP-2 began to be re-
ported. In 2008, the US Food and Drug Administration
(FDA) issued a warning about dangerous side effects as-
sociated with rhBMP-2 use in anterior cervical spine sur-
gery including dysphagia, hematoma, seroma, swelling,
and the need for intubation. Subsequent studies brought
attention to unexpected adverse events in surgical ap-
proaches outside the approved anterior lumbar approach
including radiculitus, vertebral body resorption, seroma
and/or hematoma formation, and heterotopic ossification.
Even in the approved ALIF approach, there were reported
associated with osteolysis and retrograde ejaculation [38].
A review of publicly available data in 2011 sparked the
controversy which led to this systematic review effort
asserting an underreporting of adverse events including a
risk of cancer [39].
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